Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

被引：0
|
作者：
Eide, Christopher A. [1 ,2 ]
Kurtz, Stephen E. [1 ]
Kaempf, Andy [3 ]
Long, Nicola [1 ]
Leonard, Jessica [1 ]
Chang, Bill H. [4 ]
Mori, Motomi [3 ,5 ]
Druker, Brian J. [1 ,2 ]
Tyner, Jeffrey W. [1 ,6 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA
[2] Howard Hughes Med Inst, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Biostat Shared Resource, Portland, OR 97201 USA
[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Pediat Hematol & Oncol, Portland, OR 97201 USA
[5] Oregon Hlth & Sci Univ, Sch Publ Hlth, Portland State Univ, Portland, OR 97201 USA
[6] Oregon Hlth & Sci Univ, Dept Cell Dev & Canc Biol, Portland, OR 97201 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131288
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3950
引用
收藏
页数：4
相关论文
共 50 条
  • [21] DYRK1A inhibition results in MYC and ERK activation rendering KMT2A-R acute lymphoblastic leukemia cells sensitive to BCL2 inhibition
    Ayyadevara, V. S. S. Abhinav
    Wertheim, Gerald
    Gaur, Shikha
    Chukinas, John A.
    Loftus, Joseph P.
    Lee, Sung June
    Kumar, Anil
    Swaminathan, Srividya
    Bhansali, Rahul S.
    Childers, Wayne
    Geng, Huimin
    Milne, Thomas A.
    Hua, Xianxin
    Bernt, Kathrin M.
    Besson, Thierry
    Shi, Junwei
    Crispino, John D.
    Carroll, Martin
    Tasian, Sarah K.
    Hurtz, Christian
    LEUKEMIA, 2025,
  • [22] Combined inhibition of XIAP and BCL2 drives maximal therapeutic efficacy in genetically diverse aggressive acute myeloid leukemia
    Mari Hashimoto
    Yoriko Saito
    Ryo Nakagawa
    Ikuko Ogahara
    Shinsuke Takagi
    Sadaaki Takata
    Hanae Amitani
    Mikiko Endo
    Hitomi Yuki
    Jordan A. Ramilowski
    Jessica Severin
    Ri-ichiroh Manabe
    Takashi Watanabe
    Kokoro Ozaki
    Akiko Kaneko
    Hiroshi Kajita
    Saera Fujiki
    Kaori Sato
    Teruki Honma
    Naoyuki Uchida
    Takehiro Fukami
    Yasushi Okazaki
    Osamu Ohara
    Leonard D. Shultz
    Makoto Yamada
    Shuichi Taniguchi
    Paresh Vyas
    Michiel de Hoon
    Yukihide Momozawa
    Fumihiko Ishikawa
    Nature Cancer, 2021, 2 : 340 - 356
  • [23] Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-protein-expression" lymphoma with MYC and BCL2 rearrangements
    Uchida, Akiko
    Isobe, Yasushi
    Asano, Junko
    Uemura, Yu
    Hoshikawa, Masahiro
    Takagi, Masayuki
    Miura, Ikuo
    HAEMATOLOGICA, 2019, 104 (07) : 1417 - 1421
  • [24] Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia
    Bell, Hayden L.
    Blair, Helen J.
    Gosling, Samantha J. Jepson
    Galler, Martin
    Astley, Daniel
    Moorman, Anthony V.
    Heidenreich, Olaf
    Veal, Gareth J.
    van Delft, Frederik W.
    Lunec, John
    Irving, Julie A. E.
    LEUKEMIA, 2024, 38 (06) : 1223 - 1235
  • [25] VENETOCLAX: BCL-2 INHIBITION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
    Del Poeta, G.
    Postorino, M.
    Pupo, L.
    Del Principe, M. I.
    Dal Bo, M.
    Bittolo, T.
    Buccisano, F.
    Mariotti, B.
    Iannella, E.
    Maurillo, L.
    Venditti, A.
    Gattei, V.
    de Fabritiis, P.
    Cantonetti, M.
    Amadori, S.
    DRUGS OF TODAY, 2016, 52 (04) : 249 - 260
  • [26] Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia
    Cani, Alice
    Simioni, Carolina
    Martelli, Alberto M.
    Zauli, Giorgio
    Tabellini, Giovanna
    Ultimo, Simona
    McCubrey, James A.
    Capitani, Silvano
    Neri, Luca M.
    ONCOTARGET, 2015, 6 (09) : 6597 - 6610
  • [27] Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia
    Wang, Eric
    Pineda, Jose Mario Bello
    Kim, Won Jun
    Chen, Sisi
    Bourcier, Jessie
    Stahl, Maximilian
    Hogg, Simon J.
    Bewersdorf, Jan Phillipp
    Han, Cuijuan
    Singer, Michael E.
    Cui, Daniel
    Erickson, Caroline E.
    Tittley, Steven M.
    Penson, Alexander V.
    Knorr, Katherine
    Stanley, Robert F.
    Rahman, Jahan
    Krishnamoorthy, Gnana
    Fagin, James A.
    Creger, Emily
    McMillan, Elizabeth
    Mak, Chi-Ching
    Jarvis, Matthew
    Bossard, Carine
    Beaupre, Darrin M.
    Bradley, Robert K.
    Abdel-Wahab, Omar
    CANCER CELL, 2023, 41 (01) : 164 - +
  • [28] Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Davids, Matthew S.
    Pagel, John M.
    Kahl, Brad S.
    Puvvada, Soham D.
    Gerecitano, John F.
    Kipps, Thomas J.
    Anderson, Mary Ann
    Brown, Jennifer R.
    Gressick, Lori
    Wong, Shekman
    Dunbar, Martin
    Zhu, Ming
    Desai, Monali B.
    Cerri, Elisa
    Enschede, Sari Heitner
    Humerickhouse, Rod A.
    Wierda, William G.
    Seymour, John F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04): : 311 - 322
  • [29] Promising results of BCL2 inhibition
    Diana Romero
    Nature Reviews Clinical Oncology, 2015, 12 (9) : 504 - 504
  • [30] BCL2 inhibition: back to the future!
    Dyer, Martin J. S.
    Walter, Harriet S.
    BLOOD, 2024, 143 (18) : 1787 - 1788
12345